Pilot Study of MR Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
EARLY_PHASE1
80
about 11 years
18+
Male only
1 site in CA
What this study is about
This trial is testing if magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon 13 (13C) pyruvate alone or in combination with 13C 15N2 Urea can help find prostate cancer that has poorly differentiated cells (high-grade) and is only in the original location. MRSI with hyperpolarized carbon (13C) pyruvate may assist in diagnosing prostate cancer and distinguishing high-grade from low-grade prostate cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Hyperpolarized 13C,15N2-urea
- 2.Take Hyperpolarized 13C-Pyruvate
- 3.Undergo Magnetic Resonance Spectroscopic Imaging
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
BLOOD AND BLOOD FORMING ORGANS
topical (Topical Cream)
Primary: Mean Urea AUC (Cohort B), Mean Urea AUC by pathological grade (Cohort A), Mean lactate area under curve (AUC) (Cohort B), Mean lactate area under curve (AUC) by pathological grade (Cohort A)
Secondary: Compare lactate/pyruvate area under curve (AUC) with Prostate Imaging Reporting and Data System (PI-RADS), Compare urea AUC with PI-RADS, Mean difference in Intra-patient Urea AUC, Mean difference in Intra-patient lac/pyr AUC, Optimal cut-off value of lac/pyr area under the curve (AUC) (Cohort A), Optimal cut-off value of lac/pyr area under the curve (AUC) (Cohort B), Optimal cut-off value of urea AUC (Cohort A), Optimal cut-off value of urea AUC (Cohort B)
Oncology